TriSalus Life Sciences Inc. (TLSI) - Total Liabilities
Based on the latest financial reports, TriSalus Life Sciences Inc. (TLSI) has total liabilities worth $63.19 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore TLSI year-over-year net asset growth to track the company's year-over-year net asset growth rate.
TriSalus Life Sciences Inc. - Total Liabilities Trend (2021–2024)
This chart illustrates how TriSalus Life Sciences Inc.'s total liabilities have evolved over time, based on quarterly financial data.
TriSalus Life Sciences Inc. Competitors by Total Liabilities
The table below lists competitors of TriSalus Life Sciences Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Infinity Natural Resources, Inc.
NYSE:INR
|
USA | $1.10 Billion |
|
The Lovesac Company
NASDAQ:LOVE
|
USA | $295.44 Million |
|
Pennar Industries Limited
NSE:PENIND
|
India | Rs22.62 Billion |
|
First Savings Financial Group Inc
NASDAQ:FSFG
|
USA | $2.21 Billion |
|
Chargeurs S.A.
PA:CRI
|
France | €702.90 Million |
|
Metro Mining Limited
F:6ME
|
Germany | €174.50 Million |
|
GreenTech Environmental Co Ltd
SHG:688466
|
China | CN¥1.02 Billion |
|
Taisun Enterprise Co Ltd
TW:1218
|
Taiwan | NT$2.44 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down TriSalus Life Sciences Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TriSalus Life Sciences Inc. (TLSI) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TriSalus Life Sciences Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TriSalus Life Sciences Inc. (2021–2024)
The table below shows the annual total liabilities of TriSalus Life Sciences Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $49.87 Million | -3.48% |
| 2023-12-31 | $51.66 Million | +50.54% |
| 2022-12-31 | $34.32 Million | +394.94% |
| 2021-12-31 | $6.93 Million | -- |
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemo… Read more